InsidersTradesSigma
Browse the complete record of transactions filed by Goldberg Mark Alan, Director. Director active across 2 companies, notably Glycomimetics INC. In total, 6 reports have been published. Total volume traded: €270k. The latest transaction was filed on 21 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is accessible without signup.
6 of 6 declarations
Mark Alan Goldberg is a Board Member at GlycoMimetics Inc. and Blueprint Medicines Corp. He contributes to the governance of both companies, bringing his expertise in the biopharmaceutical sector. His role is essential in guiding GlycoMimetics and Blueprint in their growth and innovation strategies.